CytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
Stock Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
Assenagon Asset Management S.A. Sells 137,271 Shares of CytomX Therapeutics, Inc. $CTMX
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade
Why Is CytomX Therapeutics Stock Falling On Wednesday?
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages
CytomX Therapeutics Target of Unusually Large Options Trading (NASDAQ:CTMX)
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts
CytomX Therapeutics to Present at Upcoming February Conferences
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of “Moderate Buy” from Brokerages
CytomX Stock Rises 31% in a Month: Here's What You Should Know
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 12-Month High – Still a Buy?
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of “Moderate Buy” by Brokerages
CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages
CytomX Therapeutics to Present at Upcoming December Investor Conferences
CytomX Therapeutics: Leaning Into The Hype, But What's Next?
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
Targeting Adhesion Molecules With ADC's: The Bet Of CytomX
CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Top Biotech Stocks Riding The Rally
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025